STOCKS TELEGRAPH

Tag: SLDB Stock Price

  • Biotech Boom: Solid Biosciences (SLDB) Stock Skyrockets On Positive Developments

    Biotech Boom: Solid Biosciences (SLDB) Stock Skyrockets On Positive Developments

    With a significant climb today, shares of Solid Biosciences Inc. (NASDAQ: SLDB) were up 48.39% on the charts at $5.98 as of the most recent check. The spike in SLDB stock follows two significant announcements.

    Motivating The INSPIRE DUCHENNE Trial’s findings

    SLDB’s Phase 1/2 INSPIRE DUCHENNE clinical study, which evaluated SGT-003, an advanced gene therapy option for Duchenne muscular dystrophy, showed encouraging preliminary results. Western blot examination of the first three study participants’ interim 90-day biopsy results showed an average microdystrophin expression of 110%. Furthermore, multiple biomarkers indicated improved muscle health and resilience.

    The study employed three distinct measurement techniques, all supporting the high expression levels of the microdystrophin transgene. Significantly, improvements in muscle integrity were indicated by decreases in important clinical indicators linked to muscle degeneration. Solid Biosciences plans to discuss a simplified approval process for the therapy with the U.S. Food and Drug Administration (FDA) by mid-2025.

    Favorable Safety Profile in Initial Participants

    SGT-003 demonstrated a favorable safety profile among the first six participants dosed by the data cutoff date of February 11, 2025. After more than 20 days of treatment, all individuals had experienced adverse events (AEs) that were characteristic of AAV gene therapy. There were no significant adverse events (SAEs) or unexpected severe reactions were reported.

    Offering of Stock to Raise $200 Million

    Concurrently, Solid Biosciences said that 35,739,810 shares of common stock will be priced at $4.03 per share in an underwritten public offering. Furthermore, 13,888,340 shares of pre-funded warrants were issued at a price of $4.029 each. The offering is scheduled to close on or around February 19, 2025, and the business expects to raise around $200 million in gross proceeds.

    The exercise price for each pre-funded warrant is $0.001 per share, and it can be exercised until it is used up completely. Solid Biosciences is selling all of the equities in this offering, strengthening the company’s financial standing as it pursues its cutting-edge gene therapy projects.

  • FDA Nod Sends Solid Biosciences (SLDB) Soaring In Extended Session

    FDA Nod Sends Solid Biosciences (SLDB) Soaring In Extended Session

    Following a crucial regulatory milestone, Solid Biosciences Inc. (NASDAQ: SLDB) saw a notable increase in the value of its shares. Tuesday’s after-hours trade saw SLDB shares increase 17.35% to $4.60. The spike was propelled by the FDA’s approval of Investigational New Drug or IND application for SGT-212, the company’s new gene therapy candidate that targets Friedreich’s ataxia (FA).

    Novel Gene Therapy

    Friedreich’s ataxia is a degenerative, multisystem illness brought on by low levels of the frataxin protein. Solid Biosciences’ SGT-212 is a novel treatment for this condition. The treatment uses an AAV-based delivery method that may be administered directly into the cerebellum via intradentate nuclei (IDN) or systemically by intravenous (IV) infusion. This dual-targeting strategy aims to address both the neurological and systemic manifestations of FA, offering a comprehensive solution for disease progression.

    Friedreich’s ataxia presents unique challenges for drug development due to the need for precise frataxin expression levels to prevent cardiac toxicity and targeted delivery to cerebellar tissues for neurological benefits. SGT-212 stands out as the only candidate addressing both cardiac and neurological complications by leveraging its dual-route delivery system.

    Preclinical Success and a Differentiated Approach

    Solid Biosciences’ preclinical studies have demonstrated the potential of SGT-212 to safely deliver frataxin to critical tissues. The results showed significant improvements in neurological function and reversal of cardiac symptoms in animal models. SLDB’s extensive research, including long-term non-human primate studies, supports its belief that targeting multiple systems via dual administration is the most effective strategy for addressing FA’s diverse impacts.

    Clinical Trials on the Horizon

    Solid Biosciences is in further plans to launch a first-in-human Phase 1b clinical trial of SGT-212 in the latter half of 2025. This open-label, dose-finding study will include both ambulatory and non-ambulatory adult patients with FA across up to three cohorts. The trial will evaluate the safety and tolerability of the dual-administration approach, with participants being monitored for up to five years post-treatment.

    Solid Biosciences (SLDB) also announced a conference call scheduled for today before the market opens, aiming to provide further details on this milestone and its broader pipeline developments.

  • What Ignited The Market For Solid Biosciences (SLDB) Stock?

    What Ignited The Market For Solid Biosciences (SLDB) Stock?

    As the US stock market continues to play out, Solid Biosciences Inc. (NASDAQ: SLDB) has seen a remarkable increase in the value of its shares during current activity. According to the most recent check, Solid Biosciences stock has risen by a significant 29.41%, closing at $7.70. This surge is underpinned by a strategic maneuver on the part of Solid Biosciences, marked by a consequential disclosure pertaining to equity.

    Solid Biosciences (SLDB) has made a distinct mark by entering into a securities purchase agreement with a discerningly selected cohort of institutional accredited investors. This agreement encapsulates a substantial private placement, amounting to approximately $108.9 million.

    This private placement is expected to close on January 11, 2024, or thereabouts, assuming the usual closing conditions are met. Notably, this private placement has been priced precisely to satisfy the strict “Minimum Price” criterion while also carefully adhering to Nasdaq standards.

    Participation in the private placement spans both novel and existing investors, comprising an illustrious consortium including Adage Capital Partners LP, Invus, Janus Henderson Investors, Bain Capital Life Sciences, Perceptive Advisors, Deerfield Management Company, RA Capital Management, Vestal Point Capital, LP, and an undisclosed life sciences investor, among other stakeholders.

    In the orchestration of this private placement, Citigroup and Cantor have assumed the roles of joint lead placement agents for SLDB. The private placement itself encompasses the sale of 16,973,103 shares of common stock by Solid Biosciences at an individual share price of $5.53. Concurrently, pre-funded warrants offering the right to acquire up to 2,712,478 shares of common stock are being proffered at a rate of $5.529 per pre-funded warrant, in lieu of common stock.

    Each pre-funded warrant is endowed with an exercise price of $0.001 per share, immediate exercisability, and maintains exercisability until complete execution. The generated net proceeds from this private placement are allocated to bolstering ongoing pipeline development initiatives, facilitating business development endeavors, and attending to working capital and overarching corporate exigencies for SLDB.